Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b
Open Access
- 6 October 2006
- Vol. 107 (9), 2254-2261
- https://doi.org/10.1002/cncr.22253
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)Journal of Clinical Oncology, 2006
- Flare in Neuropathy Following Rituximab Therapy for Waldenstrom’s MacroglobulinemiaJournal of Clinical Oncology, 2006
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trialJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Cancer and Leukemia Group B 90206Clinical Cancer Research, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell CancerJournal of Clinical Oncology, 1999
- Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trialThe Lancet, 1999
- Cytokine therapeutics: lessons from interferonalpha.Proceedings of the National Academy of Sciences, 1994